Top

Cancer Chemotherapy and Pharmacology

Published in:

01-10-2008 | Original Article

Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals

Authors: Tomohiro Nabekura, Takeshi Yamaki, Kazuyuki Ueno, Shuji Kitagawa

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2008

Abstract

Purpose

For the development of a safe and effective dual inhibitor of anticancer drug efflux transporters P-glycoprotein and multidrug resistance protein 1 (MRP1) to conquer multidrug resistance, we investigated the effects of dietary phytochemicals on the functions of P-glycoprotein and MRP1.

Methods

The effects of dietary phytochemicals on the functions of P-glycoprotein and MRP1 were investigated using P-glycoprotein-overexpressing human carcinoma KB-C2 cells and human MRP1 gene-transfected KB/MRP cells. The effects of natural compounds found in dietary supplements, herbs, and foods such as sesame, ginkgo, soybean, and licorice were evaluated.

Results

The accumulation of daunorubicin, a fluorescent substrate of P-glycoprotein, increased in the presence of sesamin, ginkgolic acid, matairesinol, glycyrrhetinic acid, glabridin, and phyllodulcin in KB-C2 cells. Glycyrrhetinic acid and matairesinol also increased the accumulation of calcein, a fluorescent substrate of MRP1, in KB/MRP cells. KB-C2 and KB/MRP cells were sensitized to anticancer drugs by glycyrrhetinic acid, showing that glycyrrhetinic acid reverses multidrug resistance. The verapamil-stimulated P-glycoprotein ATPase activity was inhibited by glycyrrhetinic acid. Glycyrrhetinic acid stimulated the ATPase activity of MRP1.

Conclusion

These results suggest that dietary phytochemicals, such as glycyrrhetinic acid found in licorice, have dual inhibitory effects on P-glycoprotein and MRP1 and might become useful to enhance the efficacy of cancer chemotherapy.

Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Shinkel AH (2000) Extensive contribution of the multidrug transporters P-glycoprotein and MRP1 to basal drug resistance. Cancer Res 60:5761–5766PubMed

Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–368PubMedCrossRef

Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF (2002) Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 302:645–650PubMedCrossRef

Bhathena SJ, Velasquez MT (2002) Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 76:1191–1201PubMed

Hirose N, Inoue T, Nishihara K, Sugano M, Akimoto K, Shimizu S, Yamada H (1991) Inhibition of cholesterol absorption and synthesis in rats by sesamin. J Lipid Res 32:629–638PubMed

Jaggy H, Koch E (1997) Chemistry and biology of alkylphenols from Ginkgo biloba L. Pharmazie 52:735–738PubMed

Johnson WW (2004) ABC transporter proteins and cellular drug resistance: P-glycoprotein and analogous transporters. In: Lu DR, Øie S (eds) Cellular drug delivery: principles and practice. Humana Press, Totowa, pp. 129–162

Kitagawa S, Nabekura T, Kamiyama S (2004) Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J Pharm Pharmacol 56:1001–1005PubMedCrossRef

Kitagawa S, Nabekura T, Kamiyama S, Takahashi T, Nakamura Y, Kashiwada Y, Ikeshiro Y (2005) Effects alkyl gallates on P-glycoprotein function. Biochem Pharmacol 70:1262–1266PubMedCrossRef

10.

Kitagawa S, Nabekura T, Takahashi T, Nakamura Y, Sakamoto H, Tano H, Hirai M, Tsukahara G (2005) Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull 28:2274–2278PubMedCrossRef

11.

Leslie EM, Mao Q, Oleschuk CJ, Deeley RG, Cole SPC (2001) Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol Pharmacol 59:1171–1180PubMed

12.

Maclennan KM, Darlington CL, Smith PF (2002) The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol 67:235–257PubMedCrossRef

13.

Nabekura T, Kamiyama S, Kitagawa S (2005) Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun 327:866–870PubMedCrossRef

14.

Nagata K, Nishitani M, Matsuo M, Kioka M, Amachi T, Ueda K (2000) Nonequivalent nucleotide trapping in the two nucleotide binding folds of the human multidrug resistance protein MRP1. J Biol Chem 275:17626–17630PubMedCrossRef

15.

Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA (1992) Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267:4854–4858PubMed

16.

Shibata S (2000) A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi 120:849–862PubMed

17.

Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234PubMedCrossRef

18.

Taguchi Y, Yoshida A, Takada Y, Komano T, Ueda K (1997) Anti-cancer drugs and glutathione stimulate vanadate-induced trapping of nucleotide in multidrug resistance-associated protein (MRP). FEBS Lett 401:11–14PubMedCrossRef

19.

Tominaga H, Ishiyama M, Ohseto F, Sasamoto K, Hamamoto T, Suzuki K, Watanabe M (1999) A water-soluble tetrazolium salt useful for calorimetric cell viability assay. Anal Commun 36:47–50CrossRef

20.

Wortelboer HM, Usta M, van Zanden JJ, van Bladeren PJ, Rietjens IMCM, Cnubben NHP (2005) Inhibition of multidrug resistance proteins MRP1 and MRP2 by a series of α,β-unsaturated carbonyl compounds. Biochem Pharmacol 69:1879–1890PubMedCrossRef

Title: Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals
Authors: Tomohiro Nabekura
Takeshi Yamaki
Kazuyuki Ueno
Shuji Kitagawa
Publication date: 01-10-2008
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 5/2008
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0676-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2008

Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer

Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment

Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model

In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors

Androgen receptor expression in prostate cancer stem cells: is there a conundrum?

Oxaliplatin-induced immune mediated thrombocytopenia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer